Neurocrine Biosciences Key Executives
This section highlights Neurocrine Biosciences's key executives, including their titles and compensation details.
Find Contacts at Neurocrine Biosciences
(Showing 0 of )
Neurocrine Biosciences Earnings
This section highlights Neurocrine Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-06 | $1.62 | $1.00 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $1.51 | $1.24 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $1.05 | $0.63 |
| Read Transcript | Q1 | 2024 | 2024-05-01 | $1.01 | $0.42 |
| Read Transcript | Q4 | 2023 | 2024-02-07 | $1.15 | $1.44 |
| Read Transcript | Q3 | 2023 | 2023-10-31 | $0.97 | $0.82 |
| Read Transcript | Q2 | 2023 | 2023-08-01 | $0.78 | $0.95 |
| Read Transcript | Q1 | 2023 | 2023-05-03 | $0.26 | $-0.79 |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
$113.16
Stock Price
$11.28B
Market Cap
1.80K
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Neurocrine Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B |
| Cost of Revenue | $34.00M | $39.70M | $23.20M | $14.30M | $10.10M |
| Gross Profit | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B |
| Gross Profit Ratio | 98.56% | 97.90% | 98.44% | 98.70% | 99.03% |
| Research and Development Expenses | $731.10M | $565.00M | $463.80M | $328.10M | $275.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.01B | $887.60M | $752.70M | $583.30M | $433.30M |
| Other Expenses | $12.50M | $143.90M | $- | $105.30M | $164.50M |
| Operating Expenses | $1.75B | $1.60B | $1.22B | $911.40M | $708.30M |
| Cost and Expenses | $1.78B | $1.64B | $1.24B | $925.70M | $718.40M |
| Interest Income | $91.00M | $- | $11.20M | $3.80M | $12.60M |
| Interest Expense | $- | $4.60M | $7.10M | $25.80M | $32.80M |
| Depreciation and Amortization | $27.10M | $21.30M | $15.60M | $10.90M | $8.60M |
| EBITDA | $610.10M | $358.00M | $264.60M | $218.70M | $336.10M |
| EBITDA Ratio | 25.90% | 18.97% | 16.73% | 18.33% | 31.31% |
| Operating Income | $570.50M | $250.90M | $249.00M | $196.90M | $318.90M |
| Operating Income Ratio | 24.22% | 13.30% | 16.73% | 17.37% | 30.49% |
| Total Other Income Expenses Net | $-84.50M | $81.20M | $-35.10M | $-1.10M | $-56.30M |
| Income Before Tax | $486.00M | $332.10M | $213.90M | $101.40M | $106.70M |
| Income Before Tax Ratio | 20.63% | 17.60% | 14.37% | 8.95% | 10.20% |
| Income Tax Expense | $144.70M | $82.40M | $59.40M | $11.80M | $-300.60M |
| Net Income | $341.30M | $249.70M | $154.50M | $89.60M | $407.30M |
| Net Income Ratio | 14.49% | 13.23% | 10.38% | 7.90% | 38.94% |
| EPS | $3.40 | $2.56 | $1.61 | $0.95 | $4.37 |
| EPS Diluted | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 |
| Weighted Average Shares Outstanding | 100.40M | 97.70M | 95.80M | 94.60M | 93.10M |
| Weighted Average Shares Outstanding Diluted | 103.70M | 101.00M | 98.90M | 97.90M | 97.80M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $627.70M | $622.10M | $590.20M | $515.30M | $515.20M | $498.80M | $452.70M | $420.40M | $412.00M | $387.90M | $378.20M | $310.60M | $312.00M | $296.00M | $288.90M | $236.60M | $247.90M | $258.50M | $302.40M | $237.10M |
| Cost of Revenue | $9.30M | $8.00M | $15.60M | $12.80M | $8.50M | $11.20M | $11.50M | $8.50M | $7.70M | $6.10M | $4.80M | $4.60M | $4.10M | $4.20M | $3.10M | $2.90M | $2.90M | $2.70M | $2.40M | $2.10M |
| Gross Profit | $618.40M | $614.10M | $574.60M | $502.50M | $506.70M | $487.60M | $441.20M | $411.90M | $404.30M | $381.80M | $373.40M | $306.00M | $307.90M | $291.80M | $285.80M | $233.70M | $245.00M | $255.80M | $300.00M | $235.00M |
| Gross Profit Ratio | 98.52% | 98.70% | 97.40% | 97.50% | 98.40% | 97.80% | 97.50% | 98.00% | 98.10% | 98.40% | 98.70% | 98.50% | 98.70% | 98.60% | 98.90% | 98.80% | 98.83% | 98.96% | 99.21% | 99.11% |
| Research and Development Expenses | $185.60M | $195.00M | $184.70M | $154.10M | $137.50M | $142.20M | $145.80M | $139.50M | $118.00M | $107.70M | $135.90M | $102.20M | $87.40M | $92.70M | $74.80M | $73.20M | $66.70M | $69.10M | $80.90M | $58.30M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $287.80M | $234.30M | $242.00M | $243.10M | $218.90M | $204.20M | $221.80M | $242.70M | $182.90M | $186.30M | $182.80M | $200.70M | $156.50M | $154.60M | $143.20M | $129.00M | $106.50M | $112.50M | $96.50M | $117.80M |
| Other Expenses | $3.00M | $1.00M | $2.50M | $-88.70M | $143.90M | $- | $- | $143.90M | $23.20M | $- | $- | $- | $119.60M | $- | $5.00M | $- | $164.50M | $118.50M | $46.00M | $- |
| Operating Expenses | $476.40M | $430.30M | $426.70M | $397.20M | $356.40M | $346.40M | $367.60M | $382.20M | $300.90M | $294.00M | $318.70M | $302.90M | $243.90M | $247.30M | $218.00M | $202.20M | $173.20M | $181.60M | $177.40M | $176.10M |
| Cost and Expenses | $485.70M | $438.30M | $442.30M | $410.00M | $364.90M | $357.60M | $379.10M | $390.70M | $308.60M | $300.10M | $323.50M | $307.50M | $248.00M | $251.50M | $221.10M | $205.10M | $176.10M | $184.30M | $179.80M | $178.20M |
| Interest Income | $- | $- | $- | $- | $20.00M | $15.60M | $12.00M | $9.80M | $8.40M | $200.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $1.10M | $1.10M | $1.10M | $1.30M | $1.10M | $1.10M | $1.20M | $2.20M | $2.60M | $6.60M | $6.60M | $6.20M | $6.40M | $7.80M | $8.50M | $8.30M | $8.20M |
| Depreciation and Amortization | $7.10M | $6.50M | $7.30M | $6.20M | $5.70M | $5.50M | $5.10M | $5.00M | $4.40M | $4.00M | $3.90M | $3.30M | $3.00M | $2.80M | $2.60M | $2.50M | $2.20M | $2.20M | $2.10M | $2.10M |
| EBITDA | $152.10M | $191.30M | $155.20M | $111.50M | $156.00M | $146.70M | $78.70M | $-97.20M | $107.80M | $91.80M | $-17.20M | $6.40M | $-4.20M | $47.30M | $70.40M | $34.00M | $74.00M | $-46.40M | $124.70M | $61.00M |
| EBITDA Ratio | 24.23% | 30.75% | 26.30% | 21.64% | 30.28% | 28.31% | 16.26% | 7.06% | 25.10% | 23.67% | 15.49% | 2.06% | 20.51% | 15.98% | 24.37% | 14.37% | 28.96% | 28.70% | 41.24% | 25.73% |
| Operating Income | $142.00M | $183.80M | $147.90M | $105.30M | $150.30M | $141.20M | $73.60M | $-114.20M | $103.40M | $87.80M | $54.70M | $3.10M | $-36.30M | $44.50M | $62.80M | $31.50M | $71.80M | $-44.30M | $76.60M | $58.90M |
| Operating Income Ratio | 22.62% | 29.55% | 25.06% | 20.43% | 29.17% | 28.31% | 16.26% | -27.16% | 25.10% | 22.63% | 14.46% | 1.00% | -11.63% | 15.03% | 21.74% | 13.31% | 28.96% | -17.14% | 25.33% | 24.84% |
| Total Other Income Expenses Net | $20.60M | $6.50M | $-46.80M | $-64.80M | $47.90M | $-25.60M | $48.00M | $10.90M | $14.50M | $10.10M | $-78.00M | $18.30M | $22.50M | $-14.00M | $-5.30M | $-4.30M | $-30.10M | $-12.80M | $6.60M | $-20.00M |
| Income Before Tax | $162.60M | $190.30M | $98.60M | $34.50M | $198.20M | $115.60M | $121.60M | $-103.30M | $117.90M | $97.90M | $-23.30M | $21.40M | $-13.80M | $30.50M | $57.50M | $27.20M | $41.70M | $-57.10M | $83.20M | $38.90M |
| Income Before Tax Ratio | 25.90% | 30.59% | 16.71% | 6.70% | 38.47% | 23.18% | 26.86% | -24.57% | 28.62% | 25.24% | -6.16% | 6.89% | -4.42% | 10.30% | 19.90% | 11.50% | 16.82% | -22.09% | 27.51% | 16.41% |
| Income Tax Expense | $59.50M | $60.50M | $33.60M | $-8.90M | $50.50M | $32.50M | $26.10M | $-26.70M | $28.90M | $29.40M | $-6.40M | $7.50M | $-6.50M | $8.00M | $15.20M | $-4.90M | $-306.20M | $500.00K | $3.60M | $1.50M |
| Net Income | $103.10M | $129.80M | $65.00M | $43.40M | $147.70M | $83.10M | $95.50M | $-76.60M | $89.00M | $68.50M | $-16.90M | $13.90M | $-7.30M | $22.50M | $42.30M | $32.10M | $347.90M | $-57.60M | $79.60M | $37.40M |
| Net Income Ratio | 16.43% | 20.86% | 11.01% | 8.42% | 28.67% | 16.66% | 21.10% | -18.22% | 21.60% | 17.66% | -4.47% | 4.48% | -2.34% | 7.60% | 14.64% | 13.57% | 140.34% | -22.28% | 26.32% | 15.77% |
| EPS | $1.03 | $1.28 | $0.64 | $0.43 | $1.50 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | $-0.18 | $0.15 | $-0.08 | $0.24 | $0.45 | $0.34 | $3.72 | $-0.62 | $0.86 | $0.40 |
| EPS Diluted | $0.99 | $1.24 | $0.63 | $0.42 | $1.44 | $0.82 | $0.95 | $-0.79 | $0.88 | $0.69 | $-0.18 | $0.14 | $-0.08 | $0.23 | $0.43 | $0.33 | $3.58 | $-0.62 | $0.81 | $0.39 |
| Weighted Average Shares Outstanding | 100.40M | 101.10M | 100.80M | 99.80M | 98.40M | 97.90M | 97.60M | 97.10M | 96.30M | 95.80M | 95.60M | 95.30M | 94.90M | 94.70M | 94.60M | 94.20M | 93.50M | 92.90M | 93.00M | 92.60M |
| Weighted Average Shares Outstanding Diluted | 103.70M | 104.30M | 103.90M | 103.60M | 102.30M | 101.10M | 100.20M | 97.10M | 100.80M | 99.00M | 95.60M | 97.60M | 94.90M | 97.70M | 97.70M | 98.20M | 97.20M | 93.30M | 98.20M | 97.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $233.00M | $251.10M | $262.90M | $340.80M | $801.00M |
| Short Term Investments | $843.10M | $780.50M | $726.40M | $370.50M | $613.90M |
| Cash and Short Term Investments | $1.08B | $1.03B | $989.30M | $711.30M | $801.00M |
| Net Receivables | $479.10M | $439.30M | $350.00M | $185.50M | $157.10M |
| Inventory | $57.40M | $38.30M | $35.10M | $30.50M | $28.00M |
| Other Current Assets | $112.10M | $97.80M | $79.10M | $45.50M | $30.10M |
| Total Current Assets | $1.72B | $1.61B | $1.45B | $972.80M | $1.02B |
| Property Plant Equipment Net | $592.00M | $347.30M | $145.60M | $155.80M | $127.40M |
| Goodwill | $- | $- | $5.40M | $- | $- |
| Intangible Assets | $36.50M | $35.50M | $37.20M | $- | $- |
| Goodwill and Intangible Assets | $36.50M | $35.50M | $37.20M | $- | $- |
| Long Term Investments | $124.80M | $849.40M | $401.50M | $624.40M | $265.30M |
| Tax Assets | $485.70M | $362.60M | $305.90M | $315.10M | $319.40M |
| Other Non-Current Assets | $755.00M | $49.60M | $25.00M | $4.40M | $6.40M |
| Total Non-Current Assets | $1.99B | $1.64B | $915.20M | $1.10B | $718.50M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B |
| Account Payables | $110.00M | $108.90M | $67.30M | $51.50M | $39.40M |
| Short Term Debt | $- | $170.10M | $169.40M | $- | $- |
| Tax Payables | $- | $24.40M | $9.00M | $- | $- |
| Deferred Revenue | $- | $- | $- | $-16.50M | $-10.30M |
| Other Current Liabilities | $397.70M | $351.40M | $292.00M | $194.30M | $147.10M |
| Total Current Liabilities | $507.70M | $654.80M | $537.70M | $245.80M | $186.50M |
| Long Term Debt | $455.10M | $258.30M | $93.50M | $440.40M | $412.30M |
| Deferred Revenue Non-Current | $- | $- | $-32.80M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $32.80M | $- | $- |
| Other Non-Current Liabilities | $166.20M | $106.30M | $29.70M | $12.30M | $9.70M |
| Total Non-Current Liabilities | $621.30M | $364.60M | $123.20M | $452.70M | $422.00M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.13B | $1.02B | $660.90M | $698.50M | $608.50M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $29.20M | $-157.10M | $-406.80M | $-635.80M | $-725.40M |
| Accumulated Other Comprehensive Income Loss | $5.80M | $7.00M | $-7.90M | $-1.70M | $1.80M |
| Other Total Stockholders Equity | $2.55B | $2.38B | $2.12B | $2.01B | $1.85B |
| Total Stockholders Equity | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B |
| Total Equity | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B |
| Total Liabilities and Stockholders Equity | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B |
| Total Investments | $967.90M | $1.63B | $1.13B | $994.90M | $879.20M |
| Total Debt | $455.10M | $428.40M | $262.90M | $440.40M | $412.30M |
| Net Debt | $222.10M | $177.30M | $- | $99.60M | $-388.70M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $233.00M | $349.10M | $139.70M | $396.30M | $251.10M | $293.70M | $160.20M | $-90.40M | $262.90M | $212.20M | $163.30M | $270.20M | $340.80M | $311.10M | $368.00M | $352.60M | $801.00M | $944.70M | $415.10M | $187.00M |
| Short Term Investments | $843.10M | $878.90M | $899.20M | $814.30M | $780.50M | $801.40M | $816.50M | $1.14B | $726.40M | $587.20M | $485.00M | $394.70M | $370.50M | $454.80M | $516.90M | $521.10M | $613.90M | $519.40M | $533.20M | $584.70M |
| Cash and Short Term Investments | $1.08B | $1.23B | $1.04B | $1.21B | $1.03B | $1.10B | $976.70M | $894.60M | $989.30M | $799.40M | $648.30M | $664.90M | $711.30M | $765.90M | $884.90M | $873.70M | $801.00M | $944.70M | $948.30M | $771.70M |
| Net Receivables | $479.10M | $481.10M | $468.20M | $450.70M | $439.30M | $417.80M | $387.60M | $391.60M | $350.00M | $301.20M | $279.00M | $263.50M | $185.50M | $163.80M | $158.50M | $147.80M | $157.10M | $156.90M | $148.40M | $148.60M |
| Inventory | $57.40M | $45.80M | $42.50M | $37.20M | $38.30M | $28.80M | $31.70M | $33.40M | $35.10M | $37.00M | $29.30M | $29.00M | $30.50M | $25.50M | $28.30M | $30.10M | $28.00M | $20.60M | $22.00M | $21.20M |
| Other Current Assets | $112.10M | $121.70M | $120.20M | $100.50M | $97.80M | $108.20M | $100.60M | $113.20M | $79.10M | $67.90M | $62.70M | $60.80M | $45.50M | $50.50M | $38.40M | $33.80M | $30.10M | $34.70M | $27.50M | $26.70M |
| Total Current Assets | $1.72B | $1.88B | $1.67B | $1.80B | $1.61B | $1.65B | $1.50B | $1.43B | $1.45B | $1.21B | $1.02B | $1.02B | $972.80M | $1.01B | $1.11B | $1.09B | $1.02B | $1.16B | $1.15B | $968.20M |
| Property Plant Equipment Net | $592.00M | $337.30M | $343.00M | $346.10M | $347.30M | $149.60M | $149.10M | $147.20M | $145.60M | $150.50M | $159.00M | $158.60M | $155.80M | $149.00M | $150.30M | $142.30M | $127.40M | $114.00M | $116.70M | $115.20M |
| Goodwill | $- | $- | $5.70M | $- | $5.80M | $- | $- | $- | $5.40M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $36.50M | $34.50M | $33.50M | $34.30M | $35.50M | $34.90M | $36.90M | $37.20M | $37.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $36.50M | $34.50M | $33.50M | $34.30M | $35.50M | $34.90M | $36.90M | $37.20M | $37.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $864.30M | $770.60M | $789.40M | $871.90M | $849.40M | $587.50M | $515.60M | $380.30M | $401.50M | $457.50M | $489.00M | $632.30M | $624.40M | $549.00M | $376.70M | $288.50M | $265.30M | $225.10M | $245.90M | $275.30M |
| Tax Assets | $485.70M | $454.40M | $419.50M | $378.20M | $362.60M | $383.20M | $379.00M | $337.40M | $305.90M | $319.40M | $328.40M | $325.30M | $315.10M | $310.40M | $316.10M | $325.60M | $319.40M | $- | $- | $- |
| Other Non-Current Assets | $15.50M | $61.60M | $49.80M | $42.90M | $49.60M | $43.10M | $35.90M | $24.90M | $25.00M | $10.50M | $10.00M | $10.10M | $4.40M | $3.20M | $3.20M | $4.60M | $6.40M | $6.60M | $6.80M | $3.20M |
| Total Non-Current Assets | $1.99B | $1.66B | $1.64B | $1.67B | $1.64B | $1.20B | $1.12B | $927.00M | $915.20M | $937.90M | $986.40M | $1.13B | $1.10B | $1.01B | $846.30M | $761.00M | $718.50M | $345.70M | $369.40M | $393.70M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.72B | $3.54B | $3.31B | $3.47B | $3.25B | $2.85B | $2.61B | $2.36B | $2.37B | $2.14B | $2.01B | $2.14B | $2.07B | $2.02B | $1.96B | $1.85B | $1.73B | $1.50B | $1.52B | $1.36B |
| Account Payables | $110.00M | $95.70M | $107.20M | $87.30M | $108.90M | $93.80M | $391.60M | $355.70M | $67.30M | $297.80M | $265.70M | $- | $51.50M | $- | $- | $- | $39.40M | $- | $- | $- |
| Short Term Debt | $- | $- | $35.40M | $157.80M | $202.10M | $187.70M | $187.40M | $- | $169.40M | $186.50M | $17.10M | $- | $- | $- | $- | $- | $- | $434.70M | $428.70M | $- |
| Tax Payables | $- | $- | $34.70M | $24.80M | $24.40M | $72.70M | $- | $- | $9.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $24.80M | $339.90M | $-93.80M | $-391.60M | $-374.10M | $- | $-297.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $397.70M | $334.00M | $221.20M | $418.20M | $319.40M | $337.40M | $3.50M | $18.40M | $292.00M | $800.00K | $2.90M | $253.50M | $194.30M | $225.90M | $212.90M | $190.00M | $147.10M | $176.30M | $144.30M | $140.30M |
| Total Current Liabilities | $507.70M | $429.70M | $398.50M | $712.90M | $654.80M | $691.60M | $582.50M | $374.10M | $537.70M | $485.10M | $285.70M | $253.50M | $245.80M | $225.90M | $212.90M | $190.00M | $186.50M | $611.00M | $573.00M | $140.30M |
| Long Term Debt | $455.10M | $251.40M | $256.20M | $252.90M | $258.30M | $85.90M | $89.10M | $259.90M | $93.50M | $96.60M | $268.60M | $480.20M | $440.40M | $437.10M | $435.30M | $429.50M | $412.30M | $83.00M | $84.30M | $499.70M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-78.60M | $- | $- | $- | $-32.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $78.60M | $- | $- | $- | $32.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $166.20M | $135.00M | $141.10M | $120.50M | $106.30M | $68.60M | $88.50M | $41.30M | $29.70M | $17.10M | $28.00M | $19.70M | $12.30M | $8.30M | $29.00M | $21.30M | $9.70M | $4.30M | $27.10M | $21.60M |
| Total Non-Current Liabilities | $621.30M | $386.40M | $397.30M | $373.40M | $364.60M | $154.50M | $177.60M | $301.20M | $123.20M | $113.70M | $296.60M | $499.90M | $452.70M | $445.40M | $464.30M | $450.80M | $422.00M | $87.30M | $111.40M | $521.30M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.13B | $816.10M | $795.80M | $1.09B | $1.02B | $846.10M | $760.10M | $675.30M | $660.90M | $598.80M | $582.30M | $753.40M | $698.50M | $671.30M | $677.20M | $640.80M | $608.50M | $698.30M | $684.40M | $661.60M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $29.20M | $81.10M | $-48.70M | $-113.70M | $-157.10M | $-304.80M | $-387.90M | $-483.40M | $-406.80M | $-495.80M | $-564.30M | $-547.40M | $-635.80M | $-628.50M | $-651.00M | $-693.30M | $-725.40M | $-1.07B | $-1.02B | $-1.10B |
| Accumulated Other Comprehensive Income Loss | $5.80M | $14.50M | $2.50M | $3.30M | $7.00M | $-1.70M | $-1.10M | $-2.70M | $-7.90M | $-14.00M | $-12.20M | $-9.30M | $-1.70M | $400.00K | $700.00K | $1.00M | $1.80M | $3.20M | $4.60M | $-1.40M |
| Other Total Stockholders Equity | $2.55B | $2.62B | $2.56B | $2.50B | $2.38B | $2.31B | $2.24B | $2.17B | $2.12B | $2.05B | $2.00B | $1.95B | $2.01B | $1.97B | $1.93B | $1.90B | $1.85B | $1.87B | $1.84B | $1.80B |
| Total Stockholders Equity | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | $1.42B | $1.39B | $1.37B | $1.35B | $1.28B | $1.21B | $1.13B | $804.30M | $831.20M | $700.30M |
| Total Equity | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | $1.42B | $1.39B | $1.37B | $1.35B | $1.28B | $1.21B | $1.13B | $804.30M | $831.20M | $700.30M |
| Total Liabilities and Stockholders Equity | $3.72B | $3.54B | $3.31B | $3.47B | $3.25B | $2.85B | $2.61B | $2.36B | $2.37B | $2.14B | $2.01B | $2.14B | $2.07B | $2.02B | $1.96B | $1.85B | $1.73B | $1.50B | $1.52B | $1.36B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.72B | $3.54B | $3.31B | $3.47B | $3.25B | $2.85B | $2.61B | $2.36B | $2.37B | $2.14B | $2.01B | $2.14B | $2.07B | $2.02B | $1.96B | $1.85B | $1.73B | $1.50B | $1.52B | $1.36B |
| Total Investments | $1.71B | $1.65B | $1.69B | $1.69B | $1.63B | $934.20M | $989.50M | $1.14B | $1.13B | $1.04B | $974.00M | $1.03B | $994.90M | $1.00B | $893.60M | $809.60M | $879.20M | $744.50M | $779.10M | $860.00M |
| Total Debt | $455.10M | $251.40M | $291.60M | $546.90M | $428.40M | $255.80M | $258.80M | $259.90M | $262.90M | $265.80M | $268.60M | $480.20M | $440.40M | $437.10M | $435.30M | $429.50M | $412.30M | $508.00M | $503.80M | $499.70M |
| Net Debt | $222.10M | $-97.70M | $151.90M | $150.60M | $177.30M | $-37.90M | $98.60M | $350.30M | $- | $53.60M | $105.30M | $210.00M | $99.60M | $126.00M | $67.30M | $76.90M | $-388.70M | $-436.70M | $88.70M | $312.70M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $341.30M | $249.70M | $154.50M | $89.60M | $407.30M |
| Depreciation and Amortization | $-2.70M | $21.30M | $15.60M | $10.90M | $8.60M |
| Deferred Income Tax | $-123.10M | $-56.70M | $19.10M | $4.30M | $-310.70M |
| Stock Based Compensation | $195.50M | $194.30M | $173.10M | $134.20M | $100.00M |
| Change in Working Capital | $- | $28.20M | $-67.40M | $16.70M | $-37.90M |
| Accounts Receivables | $-39.80M | $-89.30M | $-162.20M | $-28.40M | $-30.50M |
| Inventory | $-19.10M | $5.40M | $-2.60M | $-2.50M | $-10.70M |
| Accounts Payables | $29.00M | $64.30M | $114.60M | $56.80M | $26.90M |
| Other Working Capital | $- | $47.80M | $-17.20M | $-9.20M | $-23.60M |
| Other Non Cash Items | $184.40M | $-46.90M | $44.50M | $800.00K | $61.20M |
| Net Cash Provided by Operating Activities | $595.40M | $389.90M | $339.40M | $256.50M | $228.50M |
| Investments in Property Plant and Equipment | $-38.20M | $-28.30M | $-16.50M | $-23.40M | $-10.90M |
| Acquisitions Net | $- | $- | $-42.70M | $4.60M | $0 |
| Purchases of Investments | $-1.06B | $-1.41B | $-628.90M | $-804.70M | $-735.50M |
| Sales Maturities of Investments | $967.50M | $972.40M | $511.00M | $697.90M | $750.50M |
| Other Investing Activities | $-0 | $- | $-117.90M | $-4.60M | $15.00M |
| Net Cash Used for Investing Activities | $-126.80M | $-467.10M | $-177.10M | $-130.20M | $4.10M |
| Debt Repayment | $-308.80M | $- | $-279.00M | $-100.00K | $-186.90M |
| Common Stock Issued | $- | $65.30M | $44.70M | $27.50M | $29.10M |
| Common Stock Repurchased | $-300.00M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $122.10M | $65.30M | $- | $27.50M | $- |
| Net Cash Used Provided by Financing Activities | $-486.70M | $65.30M | $-234.30M | $27.40M | $-157.80M |
| Effect of Forex Changes on Cash | $- | $300.00K | $-1.30M | $- | $- |
| Net Change in Cash | $-18.10M | $-11.60M | $-73.30M | $153.70M | $74.80M |
| Cash at End of Period | $241.00M | $259.10M | $270.70M | $344.00M | $190.30M |
| Cash at Beginning of Period | $259.10M | $270.70M | $344.00M | $190.30M | $115.50M |
| Operating Cash Flow | $595.40M | $389.90M | $339.40M | $256.50M | $228.50M |
| Capital Expenditure | $-38.20M | $-28.30M | $-16.50M | $-23.40M | $-10.90M |
| Free Cash Flow | $557.20M | $361.60M | $322.90M | $233.10M | $217.60M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $103.10M | $129.80M | $65.00M | $43.40M | $147.70M | $83.10M | $95.50M | $-76.60M | $89.00M | $68.50M | $-16.90M | $13.90M | $-7.30M | $22.50M | $42.30M | $32.10M | $347.90M | $-57.60M | $79.60M | $37.40M |
| Depreciation and Amortization | $7.10M | $6.50M | $7.30M | $6.20M | $5.70M | $5.50M | $5.10M | $5.00M | $4.40M | $4.00M | $3.90M | $3.30M | $3.00M | $2.80M | $2.60M | $2.50M | $2.20M | $2.20M | $2.10M | $2.10M |
| Deferred Income Tax | $-31.30M | $-34.90M | $-41.30M | $-15.60M | $20.60M | $-4.20M | $-41.50M | $-31.60M | $13.50M | $9.00M | $-3.10M | $-300.00K | $-4.70M | $5.70M | $9.50M | $-6.20M | $-310.70M | $7.00M | $-11.30M | $16.50M |
| Stock Based Compensation | $66.40M | $41.50M | $43.10M | $44.50M | $38.10M | $47.80M | $68.50M | $39.90M | $43.50M | $43.10M | $49.50M | $37.00M | $35.60M | $37.10M | $28.60M | $32.90M | $21.00M | $26.70M | $29.50M | $22.80M |
| Change in Working Capital | $94.30M | $4.40M | $-86.30M | $-31.60M | $-53.70M | $46.00M | $93.40M | $-57.50M | $-1.50M | $-15.60M | $25.40M | $-75.70M | $4.90M | $-21.00M | $12.90M | $19.90M | $-2.60M | $-2.30M | $13.30M | $-46.30M |
| Accounts Receivables | $2.00M | $-12.90M | $-17.60M | $-11.30M | $-21.40M | $-30.40M | $4.20M | $-41.70M | $-46.50M | $-22.20M | $-15.50M | $-78.00M | $-21.70M | $-5.30M | $-10.70M | $9.30M | $-200.00K | $-8.50M | $300.00K | $-22.10M |
| Inventory | $-11.60M | $-3.30M | $-5.30M | $1.10M | $-900.00K | $2.90M | $1.60M | $1.80M | $3.90M | $-7.70M | $-300.00K | $1.50M | $-5.00M | $2.80M | $1.80M | $-2.10M | $-7.30M | $1.30M | $-800.00K | $-3.90M |
| Accounts Payables | $- | $39.40M | $-59.50M | $-18.60M | $-83.00M | $124.40M | $16.20M | $6.70M | $114.60M | $32.80M | $- | $11.50M | $26.90M | $8.70M | $18.00M | $11.00M | $26.90M | $33.20M | $- | $-16.20M |
| Other Working Capital | $103.90M | $-18.80M | $-3.90M | $-2.80M | $51.60M | $-50.90M | $71.40M | $-24.30M | $-73.50M | $-18.50M | $8.50M | $-10.70M | $4.70M | $-27.20M | $3.80M | $1.70M | $-22.00M | $-28.30M | $13.80M | $-4.10M |
| Other Non Cash Items | $2.90M | $10.70M | $216.90M | $169.10M | $-34.90M | $33.80M | $-41.40M | $-4.40M | $-5.90M | $-10.20M | $1.90M | $-18.70M | $-27.30M | $14.70M | $7.30M | $6.10M | $31.10M | $6.50M | $5.70M | $5.70M |
| Net Cash Provided by Operating Activities | $242.50M | $158.00M | $64.60M | $130.30M | $123.50M | $212.00M | $179.60M | $-125.20M | $143.00M | $98.80M | $138.10M | $-40.50M | $4.20M | $61.80M | $103.20M | $87.30M | $88.90M | $-17.50M | $118.90M | $38.20M |
| Investments in Property Plant and Equipment | $-7.30M | $-8.10M | $-11.60M | $-11.20M | $-5.40M | $-7.60M | $-6.80M | $-8.50M | $-1.80M | $1.70M | $-8.80M | $-7.60M | $-8.90M | $-5.70M | $-4.30M | $-4.50M | $-4.50M | $-400.00K | $-4.70M | $-1.30M |
| Acquisitions Net | $- | $- | $- | $- | $5.40M | $89.70M | $6.80M | $-2.20M | $-42.70M | $-1.70M | $- | $-12.20M | $- | $- | $- | $-700.00K | $- | $- | $- | $16.50M |
| Purchases of Investments | $-311.80M | $-232.50M | $-191.70M | $-320.10M | $-487.20M | $-362.70M | $-323.80M | $-237.50M | $-233.30M | $-134.20M | $-60.90M | $-200.50M | $-141.40M | $-280.20M | $-289.40M | $-93.70M | $-336.30M | $-110.60M | $-116.60M | $-172.00M |
| Sales Maturities of Investments | $250.80M | $265.30M | $175.10M | $276.30M | $290.80M | $273.00M | $204.70M | $203.90M | $162.20M | $71.20M | $101.10M | $176.50M | $174.00M | $159.70M | $202.90M | $161.30M | $193.10M | $136.20M | $214.70M | $206.50M |
| Other Investing Activities | $- | $- | $-16.60M | $-43.80M | $-5.40M | $-89.70M | $-6.80M | $2.20M | $-71.10M | $1.70M | $40.20M | $12.20M | $- | $- | $- | $700.00K | $- | $- | $- | $-16.50M |
| Net Cash Used for Investing Activities | $-68.30M | $24.70M | $-28.20M | $-55.00M | $-201.80M | $-97.30M | $-125.90M | $-42.10M | $-115.60M | $-61.30M | $31.40M | $-31.60M | $23.70M | $-126.20M | $-90.80M | $63.10M | $-147.70M | $25.20M | $93.40M | $33.20M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-279.00M | $- | $- | $- | $- | $-100.00K | $- | $- | $- | $- |
| Common Stock Issued | $- | $26.40M | $15.80M | $69.90M | $35.40M | $18.80M | $2.90M | $8.20M | $36.00M | $11.40M | $- | $6.10M | $27.50M | $- | $- | $15.20M | $7.50M | $2.50M | $15.80M | $3.30M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-290.00M | $26.40M | $-308.80M | $69.90M | $35.40M | $18.80M | $2.90M | $8.20M | $24.60M | $11.40M | $2.60M | $- | $1.80M | $7.50M | $3.00M | $15.20M | $-186.90M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $-290.00M | $26.40M | $-293.00M | $69.90M | $35.40M | $18.80M | $2.90M | $8.20M | $24.60M | $11.40M | $-276.40M | $6.10M | $1.80M | $7.50M | $3.00M | $15.10M | $-179.40M | $2.50M | $15.80M | $3.30M |
| Effect of Forex Changes on Cash | $-300.00K | $300.00K | $- | $- | $300.00K | $- | $- | $- | $-1.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-116.10M | $217.40M | $-256.60M | $145.20M | $-42.60M | $133.50M | $56.60M | $-159.10M | $50.70M | $48.90M | $-106.90M | $-66.00M | $29.70M | $-56.90M | $15.40M | $165.50M | $-238.20M | $10.20M | $228.10M | $74.70M |
| Cash at End of Period | $241.00M | $357.10M | $139.70M | $396.30M | $259.10M | $301.70M | $168.20M | $111.60M | $270.70M | $220.00M | $171.10M | $278.00M | $344.00M | $314.30M | $371.20M | $355.80M | $190.30M | $428.50M | $418.30M | $190.20M |
| Cash at Beginning of Period | $357.10M | $139.70M | $396.30M | $251.10M | $301.70M | $168.20M | $111.60M | $270.70M | $220.00M | $171.10M | $278.00M | $344.00M | $314.30M | $371.20M | $355.80M | $190.30M | $428.50M | $418.30M | $190.20M | $115.50M |
| Operating Cash Flow | $242.50M | $158.00M | $64.60M | $130.30M | $123.50M | $212.00M | $179.60M | $-125.20M | $143.00M | $98.80M | $138.10M | $-40.50M | $4.20M | $61.80M | $103.20M | $87.30M | $88.90M | $-17.50M | $118.90M | $38.20M |
| Capital Expenditure | $-7.30M | $-8.10M | $-11.60M | $-11.20M | $-5.40M | $-7.60M | $-6.80M | $-8.50M | $-1.80M | $1.70M | $-8.80M | $-7.60M | $-8.90M | $-5.70M | $-4.30M | $-4.50M | $-4.50M | $-400.00K | $-4.70M | $-1.30M |
| Free Cash Flow | $235.20M | $149.90M | $53.00M | $119.10M | $118.10M | $204.40M | $172.80M | $-133.70M | $141.20M | $100.50M | $129.30M | $-48.10M | $-4.70M | $56.10M | $98.90M | $82.80M | $84.40M | $-17.90M | $114.20M | $36.90M |
Neurocrine Biosciences Dividends
Explore Neurocrine Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Neurocrine Biosciences News
Read the latest news about Neurocrine Biosciences, including recent articles, headlines, and updates.
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Explore the exciting world of Neurocrine Biosciences (NBIX -1.47%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium SAN DIEGO , March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
SAN DIEGO , March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2) in development for the potential treatment of certain neurological and neuropsychiatric conditions.
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psychiatric condition. KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional impact of involuntary movements.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares, leaving them with a more than 3% loss in price on the day.
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Phil Nadeau - TD Cowen Paul Matteis - Stifel Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Cory Kasimov - Evercore David Amsellem - Piper Sandler Malcolm Kuno - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Jeffrey Hung - Morgan Stanley Charlie Moore - Baird Mohit Bansal - Wells Fargo Ash Verma - UBS Sumant Kulkarni - Canaccord Myles Minter - William Blair Laura Chico - Wedbush Securities Ami Fadia - Needham Uy Ear - Mizuho Malcolm Hoffman - BMO Capital Markets Operator Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today's call will be recorded, and I will be standing by should you need any assistance.
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO , Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided financial guidance for 2025. "I'm proud of the tremendous progress we made last year with the continued growth of INGREZZA for patients living with tardive dyskinesia or Huntington disease chorea.
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment for CAH, offers significant growth potential with first-year sales estimates of $150 million. Investors should expect volatility to accompany Q4 earnings and 2025 guidance, especially regarding CRENESSITY's initial sales figures. The earnings report is scheduled after-hours on Thursday.
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO , Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
SAN DIEGO , Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase 2 SAVITRI™ study of osavampator in adult subjects with MDD were announced in April 2024.
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO , Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights.
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device.
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH.
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic Landscape Non-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a Lifetime SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable lower, more physiologic GC dosing. The publication appears in Expert Review of Endocrinology & Metabolism.
Neurocrine price target raised to $182 from $172 at BofA
BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices, which it highlights were significantly higher than previous modeled. BofA continues to assume the congenital adrenal hyperplasia launch will be more of a 2H25 event given new-to-market restrictions from commercial payors, but notes that Neurocrine has pledged to offer a free goods program to allow endocrinologists to get familiar with Crenessity's clinical profile.
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacy Neurocrine Access Support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transformative opportunity. Peak sales are estimated at $1.47 billion by 2030. Neurocrine's pipeline includes five Phase 1, six Phase 2, and two Phase 3 programs, diversifying future growth opportunities.
Neurocrine Wins FDA Approval For Genetic Disorder Drug
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder Drug appeared first on Investor's Business Daily.
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NBIX.